Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to colchicine and/or anakinra treatment

Key Findings

• ●Mean attacks reduced from 8.3 to 1.56 per 24 weeks (P<0.001)
• ●Mean attack duration reduced from 67.2 to 18.3 hours
• ●Effective after colchicine and/or anakinra failure

Referenced in (1 disease)